The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers

Overview of attention for article published in Frontiers in oncology, September 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 23,814 followers.

The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers: Objective, This retrospective study investigated the efficacy of bevacizumab in refractory… #oncology https://t.co/8vXyj

29 Sep 2022

Reply Repost Favourite

New research: The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers: Objective This retrospective study investigated the efficacy of bevacizumab in refractory… https://t.co/gF

29 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.